A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117







List of co-cited articles
1021 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
519
11

Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
Taito Esaki, Fumihiko Hirai, Akitaka Makiyama, Takashi Seto, Hideaki Bando, Yoichi Naito, Kiyotaka Yoh, Kae Ishihara, Tomoyuki Kakizume, Kazuto Natsume,[...]. Cancer Sci 2019
21
52

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Katsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii. Cancer Sci 2008
153
11

An overview of the c-MET signaling pathway.
Shawna Leslie Organ, Ming-Sound Tsao. Ther Adv Med Oncol 2011
399
11

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis,[...]. Clin Cancer Res 2019
61
18


TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G R Oxnard, J C-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, K S Thress,[...]. Ann Oncol 2020
86
12


Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Rebecca S Heist, Lecia V Sequist, Darrell Borger, Justin F Gainor, Ronald S Arellano, Long P Le, Dora Dias-Santagata, Jeffrey W Clark, Jeffrey A Engelman, Alice T Shaw,[...]. J Thorac Oncol 2016
86
11

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Matthew J Niederst, Haichuan Hu, Hillary E Mulvey, Elizabeth L Lockerman, Angel R Garcia, Zofia Piotrowska, Lecia V Sequist, Jeffrey A Engelman. Clin Cancer Res 2015
308
10

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
10

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho,[...]. Nat Genet 2012
786
10

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa, Valentina Pirazzoli, Maria E Arcila, Caroline A Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y Janjigian, Paula J Spitzler, Mary Ann Melnick,[...]. Cancer Discov 2012
475
10

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Gillianne G Y Lai, Tse Hui Lim, John Lim, Perry J R Liew, Xue Lin Kwang, Rahul Nahar, Zaw Win Aung, Angela Takano, Yin Yeng Lee, Dawn P X Lau,[...]. J Clin Oncol 2019
47
21

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
10

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
10

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
Matthew S Lara, William S Holland, Danielle Chinn, Rebekah A Burich, Primo N Lara, David R Gandara, Karen Kelly, Philip C Mack. Clin Lung Cancer 2017
23
43


Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Yong Jia, Cai-Hong Yun, Eunyoung Park, Dalia Ercan, Mari Manuia, Jose Juarez, Chunxiao Xu, Kevin Rhee, Ting Chen, Haikuo Zhang,[...]. Nature 2016
333
9

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Magda Bahcall, Taebo Sim, Cloud P Paweletz, Jyoti D Patel, Ryan S Alden, Yanan Kuang, Adrian G Sacher, Nam Doo Kim, Christine A Lydon, Mark M Awad,[...]. Cancer Discov 2016
81
11

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang. J Thorac Oncol 2014
665
9

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
967
9

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
150
9

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Joel W Neal, Suzanne E Dahlberg, Heather A Wakelee, Seena C Aisner, Michaela Bowden, Ying Huang, David P Carbone, Gregory J Gerstner, Rachel E Lerner, Jerome L Rubin,[...]. Lancet Oncol 2016
71
12

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
191
9

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Ryoichi Onozato, Takayuki Kosaka, Hiroyuki Kuwano, Yoshitaka Sekido, Yasushi Yatabe, Tetsuya Mitsudomi. J Thorac Oncol 2009
208
9

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Jana Fassunke, Wolfgang Schulte, Yon-Dschun Ko, Andreas Schlesinger, Marc Bos,[...]. Clin Cancer Res 2015
101
9

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Qiming Wang, Sen Yang, Kai Wang, Shi-Yong Sun. J Hematol Oncol 2019
55
16

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Shuhang Wang, Yongping Song, Delong Liu. Cancer Lett 2017
102
9

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
37
24

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Ravid Straussman, Teppei Morikawa, Kevin Shee, Michal Barzily-Rokni, Zhi Rong Qian, Jinyan Du, Ashli Davis, Margaret M Mongare, Joshua Gould, Dennie T Frederick,[...]. Nature 2012
8

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
Paolo M Comoglio, Livio Trusolino, Carla Boccaccio. Nat Rev Cancer 2018
116
8

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Sai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, Adrienne Johnson, Samuel J Klempner, Viola W Zhu, Vincent A Miller, Siraj M Ali. J Thorac Oncol 2017
69
11

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou,[...]. Lancet Oncol 2015
448
8

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
8

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
James Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth O'Byrne, Jifeng Feng,[...]. Lancet Oncol 2015
959
8

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
299
8

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
323
8

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. J Clin Oncol 2018
208
8

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos. N Engl J Med 2005
8

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Lee S Rosen, Jonathan W Goldman, Alain P Algazi, P Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E Wooldridge,[...]. Clin Cancer Res 2017
40
20

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Puyu Shi, You-Take Oh, Guojing Zhang, Weilong Yao, Ping Yue, Yikun Li, Rajani Kanteti, Jacob Riehm, Ravi Salgia, Taofeek K Owonikoko,[...]. Cancer Lett 2016
89
8

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, Maria S Tretiakova, Vidya Nallasura, Edward A Fox, Mark Hansen, Erik Schaefer, Katsuhiko Naoki, Alan Lader,[...]. Cancer Res 2005
441
8

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia,[...]. J Thorac Oncol 2020
21
38

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
8

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Heounjeong Go, Yoon Kyung Jeon, Hyo Jin Park, Sook-Whan Sung, Jeong-Wook Seo, Doo Hyun Chung. J Thorac Oncol 2010
151
8

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
41
19


Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Anna Li, Jin-Ji Yang, Xu-Chao Zhang, Zhou Zhang, Jian Su, Lan-Ying Gou, Yu Bai, Qing Zhou, Zhenfan Yang, Han Han-Zhang,[...]. Clin Cancer Res 2017
46
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.